Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

INHANCE IDE de hombro inverso sin tallo

2 de noviembre de 2026 actualizado por: DePuy Orthopaedics

Estudio multicéntrico, prospectivo y aleatorizado del sistema de hombro inverso total sin vástago INHANCE

2:1 Randomized, Controlled, Multi-Center, Prospective, Pre-Market Study of the INHANCE Stemless Reverse Cementless Total Shoulder.

Descripción general del estudio

Estado

Activo, no reclutando

Condiciones

Intervención / Tratamiento

Descripción detallada

There is one primary effectiveness endpoint and there are three primary safety endpoints:

  1. Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative

  2. Primary safety endpoint(s):

    1. No revision, removal, reoperation, supplemental fixation, or other intervention for any system component
    2. No humeral or glenoid radiolucent line >2 mm is present in 50% or more zones at 2 years
    3. No conclusive evidence of migration and tilt (>5mm migration and >10° tilt) of the humeral or glenoid component at 2 years

The study will be successful if the primary effectiveness endpoint non-inferiority analysis is successfully demonstrated, and no significant difference is seen on any of the 3 primary safety endpoints.

Tipo de estudio

Intervencionista

Inscripción (Actual)

168

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Florida
      • Atlantis, Florida, Estados Unidos, 33462
        • Orthopedic Center of Palm Beach County
    • Massachusetts
      • Waltham, Massachusetts, Estados Unidos, 02451
        • Boston Bone & Joint Institute BBJI Formerly BSSC
    • Michigan
      • Grand Rapids, Michigan, Estados Unidos, 49503
        • Trinity Health Grand Rapids
    • Missouri
      • Columbia, Missouri, Estados Unidos, 65201
        • Missouri Orthopaedic Institute (MOI)
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28207
        • OrthoCarolina Research Institute Charlotte
      • Raleigh, North Carolina, Estados Unidos, 27609
        • Duke Orthopaedics of Raleigh
    • Ohio
      • Akron, Ohio, Estados Unidos, 44333
        • Crystal Clinic Orthopaedic Center
      • Cincinnati, Ohio, Estados Unidos, 45219
        • Lindner Research Center
      • Cleveland, Ohio, Estados Unidos, 44195
        • The Cleveland Clinic Foundation
    • Oregon
      • Eugene, Oregon, Estados Unidos, 97401
        • Slocum Center for Orthopaedics and Sports Medicine
    • Pennsylvania
      • Bethlehem, Pennsylvania, Estados Unidos, 18015
        • St. Luke's University Health Network
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • Rothman Orthopaedics Institute
    • Tennessee
      • Columbia, Tennessee, Estados Unidos, 38401
        • MTBJ a division of Tennessee Orthaepedic Alliance
    • Utah
      • Salt Lake City, Utah, Estados Unidos, 84108
        • University of Utah
    • Virginia
      • Fredericksburg, Virginia, Estados Unidos, 22408
        • Mary Washington Orthopedics in affiliation with FOA

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

22 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Individuals requiring reverse total shoulder replacement for a severely painful, disabling, arthritic joint (i.e. osteoarthritis, post-traumatic arthritis and rotator cuff arthropathy).
  2. Individuals who are anatomically and structurally suited to receive the implants and have a functional deltoid muscle.
  3. Individuals who are able to read and comprehend the informed patient consent document and are willing and able to provide informed patient consent for participation in the study and have authorized the transfer of their information to DePuy Synthes.
  4. Individuals who are willing and able to return for follow-up as specified by the study protocol.
  5. Individuals who are a minimum age of 22 years at the time of consent.
  6. Individuals who are willing and able to complete the Patient Reported Outcome Measure questionnaires (PROMs) as specified by the study protocol.

Exclusion Criteria:

  1. BMI > 40 kg/m2
  2. Individuals have active, uncontrolled local infection or systemic infection.
  3. Patients who have not reached skeletal maturity, regardless of age.
  4. Either preoperatively or intraoperatively and per standard of care medical assessment, bone stock in the proximal humerus or glenoid fossa is determined to be inadequate for supporting the INHANCE humeral stemless components (NOTE: exclusion applies to both arms of the study, i.e., bone stock to be evaluated independent of randomized treatment assignment).
  5. Intraoperatively and per treating physician's assessment of bone quality, bone is determined to be too soft or porous to support the implant or that is too hard or brittle to allow for proper bone preparation and fixation, i.e. osteoporosis or sclerotic bone, or tumor(s) of the supporting bone structure, where there could be considerable migration of the prosthesis and/or a chance of fracture of the humerus or glenoid.
  6. Fractures of the proximal humerus that could compromise the fixation of the INHANCE reverse humeral stemless components.
  7. Patients who have undergone previous treatment on the study shoulder that may compromise fixation of the INHANCE reverse humeral stemless component.
  8. Revision of a failed hemi, total or reverse shoulder arthroplasty.
  9. Patient is receiving, or is scheduled to receive, treatment that the Investigator considers could affect bone quality, such as chemotherapy or high dose corticosteroids.
  10. Individuals who are bedridden per the Investigator's determination.
  11. Individuals that have participated in a clinical investigation with an investigational product (drug or device) in the last three months.
  12. Individuals currently involved in any personal injury litigation, medical-legal or worker's compensation claims.
  13. Individuals, in the opinion of the Investigator, who are drug or alcohol abusers or have psychological disorders that could affect their ability to complete patient reported questionnaires or be compliant with follow-up requirements.
  14. Patients with a known medical condition that the Investigator believes would impact the study outcomes (including, but not limited to osteomyelitis, Paget's disease, neuropathies such as Charcot's disease, metastatic or neoplastic disorders).
  15. Patient has a medical condition with less than 2 years life expectancy.
  16. Patients who are known to be pregnant or breastfeeding.
  17. Known polyethylene and/or metal sensitivity or allergy.
  18. Contralateral side has been enrolled in the study or has received a total shoulder operation within the last 6 months
  19. Otherwise determined by the investigator to be medically unsuitable for participation in this study
  20. Patient is a member of a vulnerable population (i.e., incarcerated individuals - those incarcerated for at least one month and considered to be an inmate)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: INHANCE Stemless Reverse

INHANCE(TM) Stemless Reverse Total Shoulder

Uncemented Reverse Total Shoulder

Comparador activo: INHANCE Stemmed Reverse

INHANCE(TM) Stemmed Reverse Total Shoulder

Uncemented Reverse Total Shoulder

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Constant Murley Score (CMS)
Periodo de tiempo: Pre-op, 2 years

Primary effectiveness endpoint - Adjusted Constant-Murley Change from Baseline (ACM CFB) at 2 years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 2 years
Removal of any system component
Periodo de tiempo: 2 year

No removal of any system component

2 year
Revision of any system component
Periodo de tiempo: 2 year

No revision of any system component

2 year
Reoperation of any system component
Periodo de tiempo: 2 year

No reoperation of any system component

2 year
Supplemental Fixation of any system component
Periodo de tiempo: 2 year

No supplemental fixation of any system component

2 year
Radiolucent Lines (Humeral & Glenoid)
Periodo de tiempo: 2 year

No humeral or glenoid radiolucent line greater than 2mm is present in 50% or more zones

2 year
Migration and Tilt (Humeral & Glenoid)
Periodo de tiempo: 2 year

No conclusive evidence of migration and tilt (greater than 5mm migration and greater than 10 degrees tilt) of the humeral or glenoid component

2 year

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Constant Murley Score (CMS)
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year

Adjusted Constant-Murley Score at baseline and 3- and 6-months and 1- and 2-years post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 3-month, 6-month, 1 year, 2 year
EQ-5D-5L and EQ-VAS
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year

EQ-5D-5L Scores by dimension and EQ-VAS, at baseline and 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Simple Shoulder Test
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year

Simple Shoulder Test (SST) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Single Assessment Numeric Evaluation (SANE) Score
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year

Single Assessment Numeric Evaluation (SANE) Scores at baseline and 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal".

Pre-op, 3-month, 6-month, 1 year, 2 year
Survivorship
Periodo de tiempo: 2 year

Overall survivorship of the INHANCE Shoulder System at 2 years post-operative, where the system is deemed to be surviving if no components (humeral stem or stemless component, glenosphere, baseplate, liner, etc.) have been removed for any reason, will be presented using the Kaplan-Meier method.

2 year
Complications
Periodo de tiempo: 2 year

The type and frequency of all reportable adverse events (AEs) and device deficiencies in this study will be summarized, with distinction of serious AEs, device and procedure related AEs

2 year

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
Constant Murley Score (CMS)
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year

Change from baseline adjusted Constant-Murley Score at 3- and 6-months and 1- year post-operative. The CMS is a 100 point scale, the higher the score, the higher the quality of the function. ACM will be obtained by dividing the raw score by the relative score.

Pre-op, 3-month, 6-month, 1 year
EQ-5D-5L and EQ-VAS
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline EQ-5D-5L Value Score and EQ-VAS, at 3- and 6-months and 1- and 2-years post-operative. The value score generally ranges from less than 0 to 1, with higher scores indicating higher health utility. The EQ VAS records the subject's self-rated health from 0 (worst) to 100 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Simple Shoulder Test
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline SST Scores at 3- and 6-months and 1- and 2-years post-operative. Scores range from 0 (worst) to 12 (best).

Pre-op, 3-month, 6-month, 1 year, 2 year
Single Assessment Numeric Evaluation (SANE) Score
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline SANE Scores at 3- and 6-months and 1- and 2-years post-operative. The scale is 0 to 100 with 100 being "normal".

Pre-op, 3-month, 6-month, 1 year, 2 year
Range of Motion
Periodo de tiempo: Pre-op, 3-month, 6-month, 1 year, 2 year

Change from baseline range of motion at 3- and 6-months and 1- and 2-years post-operative

Pre-op, 3-month, 6-month, 1 year, 2 year

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

4 de marzo de 2025

Finalización primaria (Estimado)

10 de noviembre de 2027

Finalización del estudio (Estimado)

30 de octubre de 2028

Fechas de registro del estudio

Enviado por primera vez

27 de febrero de 2024

Primero enviado que cumplió con los criterios de control de calidad

15 de marzo de 2024

Publicado por primera vez (Actual)

21 de marzo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

3 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • DSM202108
  • DSM202108 (Otro identificador: DePuy Orthopaedics)

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .